4 recherche sur le mot-clé 'Mood stabilizer'

Is Valacyclovir a Mood Stabilizer / Theodore A HENDERSON in Autism - Open Access, 3-3 (December 2013)  

Public ISBD [article]  inAutism - Open Access > 3-3 (December 2013) . - 4 p. Titre : Is Valacyclovir a Mood Stabilizer Type de document : Texte imprimé et/ou numérique Auteurs : Theodore A HENDERSON, Auteur Année de publication : 2013 Article en page(s) : 4 p. Langues : Anglais (eng) Mots-clés : Valacyclovir  Autism  Bipolar disorder  Mood stabilizer Index. décimale : PER Périodiques Résumé : Growing evidence indicates the role of viral agents in neuropsychiatric conditions, such as chronic fatigue syndrome (CFS), Alzheimer’s disease, and possibly autism. This case report describes a patient who was afflicted with treatment-resistant childhood bipolar disorder, who also had features associated with attention deficit hyperactivity disorder and autism spectrum disorder. After failing multiple regimens for mood stabilization (anticonvulsants, lithium, neuroleptics), a trial of valacyclovir was initiated. The decision to use an antiviral agent was based on the patient’s laboratory data and the marked treatment response of the patient’s sibling, who manifested symptoms of depression and CFS. The patient in this report showed a dramatic improvement in his volatile mood, irritability, concentration, social reciprocity, and overall personality. He was maintained on valacyclovir at 1000 mg BID, while the doses of the mood stabilizing agents and stimulants were reduced by as much as 50%. After 37 months of ongoing valacyclovir treatment, the patient continues to make improvements and is being mainstreamed in school. The case illustrates a potential role of viruses in neuropsychiatric and psychiatric disorders and the potential benefit of antiviral therapy in treatment-refractory cases. En ligne : http://dx.doi.org/10.4172/2165-7890.1000118 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228 [article] Is Valacyclovir a Mood Stabilizer [Texte imprimé et/ou numérique] / Theodore A HENDERSON, Auteur . - 2013 . - 4 p. Langues : Anglais (eng) in Autism - Open Access > 3-3 (December 2013) . - 4 p. Mots-clés : Valacyclovir  Autism  Bipolar disorder  Mood stabilizer Index. décimale : PER Périodiques Résumé : Growing evidence indicates the role of viral agents in neuropsychiatric conditions, such as chronic fatigue syndrome (CFS), Alzheimer’s disease, and possibly autism. This case report describes a patient who was afflicted with treatment-resistant childhood bipolar disorder, who also had features associated with attention deficit hyperactivity disorder and autism spectrum disorder. After failing multiple regimens for mood stabilization (anticonvulsants, lithium, neuroleptics), a trial of valacyclovir was initiated. The decision to use an antiviral agent was based on the patient’s laboratory data and the marked treatment response of the patient’s sibling, who manifested symptoms of depression and CFS. The patient in this report showed a dramatic improvement in his volatile mood, irritability, concentration, social reciprocity, and overall personality. He was maintained on valacyclovir at 1000 mg BID, while the doses of the mood stabilizing agents and stimulants were reduced by as much as 50%. After 37 months of ongoing valacyclovir treatment, the patient continues to make improvements and is being mainstreamed in school. The case illustrates a potential role of viruses in neuropsychiatric and psychiatric disorders and the potential benefit of antiviral therapy in treatment-refractory cases. En ligne : http://dx.doi.org/10.4172/2165-7890.1000118 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228

Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder / Covadonga M. DIAZ-CANEJA in Journal of Child Psychology and Psychiatry, 55-9 (September 2014)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980 Titre : Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder Type de document : Texte imprimé et/ou numérique Auteurs : Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur Article en page(s) : p.959-980 Langues : Anglais (eng) Mots-clés : Bipolar  mania  maintenance  mood stabilizer  antipsychotic  child  adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238 [article] Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder [Texte imprimé et/ou numérique] / Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur . - p.959-980. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980 Mots-clés : Bipolar  mania  maintenance  mood stabilizer  antipsychotic  child  adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238

Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis / Tomoya HIROTA in Journal of Autism and Developmental Disorders, 44-4 (April 2014)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.948-957 Titre : Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis Type de document : Texte imprimé et/ou numérique Auteurs : Tomoya HIROTA, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur ; Eric HOLLANDER, Auteur ; Taro KISHI, Auteur Année de publication : 2014 Article en page(s) : p.948-957 Langues : Anglais (eng) Mots-clés : Antiepileptic  Mood stabilizer  Anticonvulsant  Autism  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : Electroencephalogram-recorded epileptiform activity is common in children with autism spectrum disorder (ASD), even without clinical seizures. A systematic literature search identified 7 randomized, placebo-controlled trials of antiepileptic drugs (AEDs) in ASD (total n = 171), including three of valproate, and one each of lamotrigine, levetiracetam, and topiramate. Meta-analysis revealed no significant difference between medication and placebo in four studies targeting irritability/agitation and three studies investigating global improvement, although limitations include lack of power and different medications with diverse actions. Across all seven studies, there was no significant difference in discontinuation rate between two groups. AEDs do not appear to have a large effect size to treat behavioral symptoms in ASD, but further research is needed, particularly in the subgroup of patients with epileptiform abnormalities. En ligne : http://dx.doi.org/10.1007/s10803-013-1952-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228 [article] Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis [Texte imprimé et/ou numérique] / Tomoya HIROTA, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur ; Eric HOLLANDER, Auteur ; Taro KISHI, Auteur . - 2014 . - p.948-957. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.948-957 Mots-clés : Antiepileptic  Mood stabilizer  Anticonvulsant  Autism  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : Electroencephalogram-recorded epileptiform activity is common in children with autism spectrum disorder (ASD), even without clinical seizures. A systematic literature search identified 7 randomized, placebo-controlled trials of antiepileptic drugs (AEDs) in ASD (total n = 171), including three of valproate, and one each of lamotrigine, levetiracetam, and topiramate. Meta-analysis revealed no significant difference between medication and placebo in four studies targeting irritability/agitation and three studies investigating global improvement, although limitations include lack of power and different medications with diverse actions. Across all seven studies, there was no significant difference in discontinuation rate between two groups. AEDs do not appear to have a large effect size to treat behavioral symptoms in ASD, but further research is needed, particularly in the subgroup of patients with epileptiform abnormalities. En ligne : http://dx.doi.org/10.1007/s10803-013-1952-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228

Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder / Jessica F. DOUGLAS in Journal of Autism and Developmental Disorders, 43-5 (May 2013)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 43-5 (May 2013) . - p.1243-1247 Titre : Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Jessica F. DOUGLAS, Auteur ; Kevin B. SANDERS, Auteur ; M. Hannah BENNEYWORTH, Auteur ; Jessica L. SMITH, Auteur ; Virginia M. DEJEAN, Auteur ; Susan G. MCGREW, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur Article en page(s) : p.1243-1247 Langues : Anglais (eng) Mots-clés : Antiepileptic  Anticonvulsant  Mood stabilizer  Sodium channel  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5–21) and taking two other psychotropic medications (range 0–4). Fourteen patients (47 %) had a clinical global impression of improvement score of ‘much improved’ during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution. En ligne : http://dx.doi.org/10.1007/s10803-012-1661-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=195 [article] Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Jessica F. DOUGLAS, Auteur ; Kevin B. SANDERS, Auteur ; M. Hannah BENNEYWORTH, Auteur ; Jessica L. SMITH, Auteur ; Virginia M. DEJEAN, Auteur ; Susan G. MCGREW, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur . - p.1243-1247. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 43-5 (May 2013) . - p.1243-1247 Mots-clés : Antiepileptic  Anticonvulsant  Mood stabilizer  Sodium channel  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5–21) and taking two other psychotropic medications (range 0–4). Fourteen patients (47 %) had a clinical global impression of improvement score of ‘much improved’ during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution. En ligne : http://dx.doi.org/10.1007/s10803-012-1661-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=195